Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer immunotherapies. Co. has four clinical-stage investigational products: AB928, which is an orally bioavailable, reversible antagonist of the adenosine 2a and adenosine 2b receptors; AB154, which promotes sustained immune activation and tumor clearance in combination with proven immunotherapy strategies; Zimberelimab, which enables the development of precision combination regimens with full line-of-sight to the commercialization of therapies for all patients; and AB680, which is a potent and selective small-molecule to provide differential benefits relative to monoclonal antibodies. The RCUS stock yearly return is shown above.
The yearly return on the RCUS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RCUS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|